Page last updated: 2024-08-24

valsartan and Nasopharyngeal Carcinoma

valsartan has been researched along with Nasopharyngeal Carcinoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chien, CY; Lin, YT; Su, YY; Tsai, MH; Wang, HC; Yang, MY	1

Other Studies

1 other study(ies) available for valsartan and Nasopharyngeal Carcinoma

Article	Year
Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoptosis related to PI3K/AKT signaling in nasopharyngeal carcinoma. Cancer, 2021, 05-15, Volume: 127, Issue:10 Topics: Angiotensin Receptor Antagonists; Apoptosis; Humans; Losartan; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Retrospective Studies; Signal Transduction; Survival Rate; Treatment Outcome; Valsartan	2021

Article

Year

Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoptosis related to PI3K/AKT signaling in nasopharyngeal carcinoma.

Cancer, 2021, 05-15, Volume: 127, Issue:10

Topics: Angiotensin Receptor Antagonists; Apoptosis; Humans; Losartan; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Retrospective Studies; Signal Transduction; Survival Rate; Treatment Outcome; Valsartan

2021